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INTRODUCTION 
 Malignant Round Blue Cell Tumors comprise a diverse group of   
diagnostically challenging primitive (or) undifferentiated neoplasms which 
composed of small cells with uniform round nuclei and scanty cytoplasm have 
been referred as small-cell, round-cell, or blue cell tumors. “Round” refers to 
uniform shape of the nuclei, “blue” to colour of the nuclei on routine 
hematoxylin and eosin staining and “small” to the relative lack of cytoplasm. 
The “small cells” of small cell tumors are larger than most inflammatory cells84. 
The tumors included in this category of neoplasms are as follows13, 49,74,81,83, 
1. Non Hodgkin’s Lymphoma  
2. Ewing’s sarcoma /Primitive neuroectodermal tumor (PNET) 
3. Embryonal and Alveolar Rhabdomyosarcoma 
4. Wilm’s tumor  
5. Neuroblastoma  
6. Desmoplastic Small Round Cell Tumor (DSRCT) 
7. Mesenchymal Chondrosarcoma 
8. Small cell Osteosarcoma  
9. Small cell carcinoma  
10. Malignant Rhabdoid tumor 
11. Myxoid Chondrosarcoma 
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12. Poorly differentiated synovial sarcoma  
13. Round cell Liposarcoma  
14. Epithelioid sarcoma with rhabdoid phenotype 
15. Retinoblastoma 
16. Medulloblastoma  
Immunohistochemistry (IHC) and molecular diagnostics have greatly 
improved our ability to differentiate the various tumors and classify some of 
these tumors10, 81. Use of the special diagnostic techniques have become 
increasingly important in diagnosis, evaluation of recurrent or metastatic 
disease, and in some cases for prognostic classification. These are always to be 
interpreted after careful evaluation of the light microscopic findings. However, 
the more we use these tools diagnostically, the more it becomes apparent that 
these special techniques have pitfalls of their own43,56. Finally, additional 
techniques such as flow cytometry, electron microscopy and molecular analysis 
may be required for final confirmation of the diagnosis (or) to provide 
prognostic information52, 53. 
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AIM OF THE STUDY 
 
1. To find out the incidence of Malignant Round Blue Cell Tumors in and 
around Madurai.  
2.  To know the age and sex incidence of Malignant Round Blue Cell 
Tumors.  
3. To correlate the clinical and histopathological features of Malignant 
Round Blue Cell Tumors.  
4. To study the role of special stains in selected cases.  
5. To confirm the histopathological diagnosis by Immunohistochemistry 
wherever necessary.  
6. To classify the Malignant Round Blue Cell Tumors by 
Immunohistochemistry 
7. To aid the clinicians for the management of the patients.  
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REVIEW OF LITERATURE 
Nomenclature  
 Neoplasia means new growth. The term ‘Tumor’ is originally applied to 
the swelling caused by inflammation, but the non neoplastic usage of tumor has 
almost vanished. The term tumor is now equated with neoplasm. Oncology 
(Greek oncos=tumor) is the study of tumors or neoplasm.  
 The eminent British Oncologist Willis has come closest: “A neoplasm is 
an abnormal mass of tissue, the growth of which exceeds and is uncoordinated 
with that of the normal tissues and persists in the same excessive manner after 
cessation of the stimuli which evoked the change”83.  
 Neoplasms are generally divided into  
1. Benign  
2. Malignant  
Benign tumors 
  In which both microscopic and gross characteristics are considered 
relatively innocent. It will remain localized. It cannot spread to other sites, and 
it is generally amenable to surgical removal.  
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Malignant tumors  
 These are collectively referred to as cancers, derived from Latin word for 
‘crab’, because they adhere to any part that they seize on in an obstinate 
manner. Malignant tumors invade and destroy adjacent structures and spread to 
distant sites (metastasize) to cause death83.  
Definition of small round cell tumors  
“Denny” defined the characteristics of round blue cell tumors. Malignant 
Round Blue Cell Tumors can be defined in terms of clinical and pathological 
features i.e. the routine histological, immunohistochemical and ultrastructural 
features and by genetic markers. Although microarray analyses can discriminate 
between types of these tumors, a competent pathologist can do it with equal 
accuracy by using routine histological and ancillary morphologic techniques18.  
Malignant Round Blue Cell Tumors – Table -1 
Basic conventional spectrum  
1. Neuroblastoma (NB) 
2. Ewing’s sarcoma / peripheral (primitive) neuroectodermal tumor 
(ES/PNET) 
3. Rhabdomyosarcoma (RMS) 
4. Non Hodgkin’s lymphoma (NHL) 
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Extended spectrum  
1. Desmoplastic small round cell tumor (DSRCT) 
2. Small cell undifferentiated Osteosarcoma (UOS) 
3. Small cell Hepatoblastoma  
4. Wilm’s tumor (WT) 
5. Small cell variant of synovial peripheral nerve sheath tumors (MPNST) 
6. Small cell variant of synovial sarcoma (SS) 
7. Undifferentiated Small Round cell Tumor (SRCT).  
Accurate diagnosis of the tumor type is necessary for selection of 
appropriate treatment protocol73. The clinical scenario, primary site, metastatic 
pattern, gross and microscopic findings are useful to conclude the diagnosis 
whereas other features such as immunohistochemistry, electron microscopy and 
genetic features provide definitive criteria for the diagnosis26,27. Treatment 
modality varies with each tumor type, so accurate diagnosis of the tumor type is 
mandatory. For example, a therapeutic protocol for Ewing’s sarcoma is 
chemotherapy and local radiotherapy whereas surgery is not mandatory. The 
Neuroblastoma can be cured by surgical excision35,48. 
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                                                  Table-2 
Classification of small round cell tumors62 
 
 
Traditional Revised 
1. Ewing’s  sarcoma  
2. Neuroblastoma  
3. Rhabdomyosarcoma  
4. Lymphoma  
1. pPNET (Bone and soft tissue)  
a. Ewing’s sarcoma  
b. Peripheral neuroepithelioma  
c. ‘Askin’ tumor of chest wall 
d. PNET of bone  
e. Extra osseous Ewing’s (Neural) 
2. Round cell bone tumors  
a. Small cell Osteosarcoma  
b. Mesenchymal Chondrosarcoma  
c. Primitive sarcoma of bone  
3. Round cell soft tissue sarcoma 
a. Poorly differentiated Rhabdomyosarcoma  
b. Extra osseous Ewing’s (non neural)  
4.  Metastatic Neuroblastoma  
5. Extra nodal lymphoma  
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ANALYSIS OF INDIVIDUAL TUMOR 
CHARACTERISTIC  
HISTORICAL PERSPECTIVE  
Non Hodgkin’s Lymphoma 
  In 1858 Rudolph Virchow, a great German pathologist described  
lymphoma as a primary malignant neoplasm of the lymphoid tissue, which 
includes Hodgkin’s lymphoma (HL) and Non Hodgkin’s lymphoma (NHL)11. 
In 1863, he described lymphoma as malignant tumor derived from lymphoid 
cells known as “Lymphosarcoma”.  
In 1871, Billroth used the term “Malignant lymphoma”. In 1893 
Dreshfeld and Kundrat made the first attempt to delineate subcategories of 
lymphoma. In 1908, Sternberg described an aggressive mediastinal tumor in 
young males, initially known as “Sternberg sarcoma” and later recognized as 
Lymphoblastic Lymphoma. In 1913 J.Ewings suggested that the tumor was 
derived from reticulum cells..In 1923 Evald introduced the term 
‘Reticuloendotheliosis’ to represent hyperplasia of reticuloendothelial tissue11. 
In 1928, C.Oberling introduced the term ‘Reticulosarcoma’ for neoplasm 
derived from lymphoreticular system. 
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Ewing’s sarcoma / PNET 
 In 1921, James Ewing reported a tumor in radius which is composed of 
round cells and calling it as a “Diffuse endothelioma of bone” and proposing an 
endothelial derivation78.  
In 1928, OBERLING introduced the term Ewing’s sarcoma, which was a 
non-committal name to the cell of origin. Seemayer et al described peripheral 
neuroectodermal tumors (PNETs) which were unrelated to peripheral (or) 
sympathetic nervous system78. 
 In 1979 Askin et al described the “malignant small cell tumor of the 
thoracopulmonary region” (Askin tumor) having histological features similar to 
that of PNETs.32, 47 
 Identification of common cytogenetic abnormality t (11;22) q (24;12) in 
Ewing’s sarcoma and PNET favours the hypothesis that these two are 
histogenetically related. Ewing’s sarcoma and PNET collectively called as 
“Ewing Family of Tumors”, form a single neoplastic entity sharing common 
histological and molecular features, and differing only in their extent of cellular 
differentiation5, 16.  
Rhabdomyosarcoma (RMS) 
  RMS was first described by Webber19. Masson referred the RMS as 
“Rhabdopoietic sarcomas”.  RMS is a malignant tumor of mesenchymal origin.  
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 RMS is thought to arise from immature mesenchymal cells that are 
committed to skeletal muscle lineage. But these tumors can arise in tissues in 
which striated muscle is not normally found.eg. Urinary bladder14. 
 Wilm’s tumor  
In 1814 Wilm’s tumor was reported by Rance. In 1899 the condition was 
named after Carl Max Wilhelm Wilms, a German doctor who was one of the 
person, first to study this disease. In 1964 Miller and Colleague reported an 
association between aniridia and Wilm’s tumor. Subsequently, a rare complex 
of developmental anomalies including aniridia, genitourinary malformation and 
mental retardation were identified and known as WAGR syndrome7.  
The synonyms used for Wilm’s tumor includes nephroblastoma, 
embryoma, carcinosarcoma, adenosarcoma and adenomyosarcoma38.  
Neuroblastoma 
 In 1864 Virchow first described its histological appearance and 
published an article entitled “Hyperplasia of the pineal and suprarenal glands” 
and he noted nodular distension of the suprarenal gland with three or more pea 
or cherry sized swelling which arose from the adrenal medulla23.  
Virchow described large numbers of sympathetic cells apart from the 
usual elements of adrenal medulla and he classified these tumors with gliomas 
at that time23. 
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 In 1901, W.Pepper reported a study of “congenital sarcoma of the liver 
and suprarenal gland”. These were probably the first patients with the disease 
type, now described as stage 4s Neuroblastoma23. 
 In 1910 J.H.Wright first used the term Neuroblastoma. He noted that the 
migration of primitive nerve cells during embryogenesis explained the 
development of tumors of similar appearance in various sites of the body23. 
 J.B.Beckwith and R.F.Martin defined a method of grading of tumors 
from 1 to 4 depending on the degree of differentiation, and equated lymphocyte 
infiltration of the neoplasm with a better prognosis. H.Shimada et al developed 
a grading system based on mitosis, karyorrehexis index, amount of stroma and 
the patient’s age23.    
Mesenchymal Chondrosarcoma  
        This rare neoplasm was first described by Lichtenstein and Bernstein in 
1959 as an unusual variant of Chondrosarcoma which usually affects bone and 
soft tissue49,84. 
Small cell Osteosarcoma 
          This tumor is a distinctive microscopic variant of Osteosarcoma, 
described in 1979, as a tumor simulating Ewing’s sarcoma. They appear to 
represent a definite histological entity and the prognosis may be  worse for these 
lesions than conventional Osteosarcoma.  
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It is most important not to misdiagnose this tumor as Ewing's sarcoma 
because it appears not to be radiosensitive. Radical surgery and modern 
adjuvant chemotherapy seem to offer the best chance of cure22,49. 
Incidence of Malignant Round Blue Cell Tumors  
   In India lymphoma is the second most common childhood tumor after 
acute leukemia, but in developed countries central nervous (CNS) tumors are 
the second most common and lymphomas are in third place. In India the overall 
incidence of Non Hodgkin’s Lymphoma in males is 3.2% and 1.7% in 
females82.          
            Ewing’s sarcoma / PNET constitute around 6-10% of primary malignant 
bone tumors and  is the second most common primary malignant bone tumor. 
Extra skeletal Ewing’s is the second most common pediatric soft tissue 
sarcoma61,71.  
          Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma 
composed of 80-90% of reported cases74,76.    
              Wilm’s tumor affects 1 per 10,000 children worldwide before the age 
of 15, and ranks fifth in incidence among the solid tumors of the childhood, 
following central nervous tumor, lymphoma, Neuroblastoma and soft tissue 
sarcoma31,55,70. 
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           Neuroblastoma is the most common extra cranial solid tumor in children, 
and the most frequently diagnosed tumor of infancy. It occurs at a rate of 1 per 
10000 live births. It accounts for 7-8% of all paediatric malignant tumors70,79.  
Age and sex 
           In children Non Hodgkin’s lymphoma is less common than Hodgkin’s 
lymphoma but it is reverse in adults82. Surveillance Epidemiology and End 
Results (National Cancer Institute.USA) showed 67 years as the median age at 
diagnosis of NHL. Non Hodgkin’s Lymphoma predominantly affects males 
with a male: female ratio of 1.4:180.               
 Wilkins et al states that Ewing’s sarcoma occurs between the age group 
of 5 to 20 years with a distinct male preponderance86. Carvajal R et al found 
that common age group for Ewing’s sarcoma / PNET is 10-20 years, with a 
slight male predominance6.  
           Embryonal type of Rhabdomyosarcoma (RMS) affects children 
commonly below 15 yrs. Alveolar RMS affects mainly those between the ages 
of 10-25 years74. 
 Michael et al found that RMS occurred in younger than 21 years in most 
of the patients51. Simona Ognjanovic et al found a male predominance in 
Rhabdomyosarcoma with a male: female ratio of 1.37:176.  
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Mir Mahmood Seyed Ahadi et al found that mean age at the time of 
diagnosis of Wilm’s tumor was 45.2 months (4years) with a male: female ratio 
being 1.2:155.  
Norman Breslow et al found that median age at diagnosis of Wilm’s 
tumor was 36.5months and 42.5 months for males and females respectively 
with slight preponderance of females in the National Wilm’s tumor study 
registered between October 1969 and December 198557. 
Neuroblastoma develops in younger age group than Rhabdomyosarcoma 
and ES/PNETs. 50% of cases are diagnosed by the age of 2 yrs and 90% by the 
age of 5 yrs. Peak age at diagnosis is 18 months74. Gregory Hale et al found a 
slight male predominance with a male to male female ratio of 1.3:128.  
Desmoplastic small round cell tumor (DSRCT) occurs in the age group 
of 15-35 years38. Ordonez NG et al found a male preponderance with a male: 
female ratio of 4:159. 
 Small cell Osteosarcoma occurs between 10 to 25 years of age group and 
also in preschool children with slight male predominance (1.5:1)38. 
Extraskeletal Mesenchymal Chondrosarcoma occurs between the age group of 
15-35 yrs of age with a female preponderance38,74.  
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Common locations of Malignant Round Blue Cell Tumors 
                                                Table-3 
Non Hodgkin lymphoma  Lymphnode  
Ewing’s sarcoma / PNET Bone, soft tissue 
Rhabdomyosarcoma  Soft tissue  
Wilm’s tumor  Kidney  
Neuroblastoma Adrenals, Sympathetic nervous system
Desmoplastic small round cell tumor 
(DSRCT) 
Retroperitoneum  
Small cell Osteosarcoma  Bone  
Extraskeletal Mesenchymal 
Chondrosarcoma  
Soft tissue  
  
Clinical features  
Non Hodgkin’s Lymphoma (NHL) 
NHLs present as enlarged non tender lymphnodes (often >2 cm) in more 
than two third of cases. The remaining one third of NHLs present with 
symptoms related to the extranodal site83. Antoria M.S.Muller found that extra 
nodal NHL constitutes 20-30% of all NHL4. Philip Saleem et al states that 
gastro intestinal NHL (49.5%) is the most common extra nodal site followed by 
Waldayer’s ring (19%), bone, skin, breast, ovary, thyroid and parotid63.  
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Ewing’s sarcoma / PNET 
These tumors clinically simulate osteomyelitis because of pain, fever and 
leukocytosis49. Kissane et al found that Ewing’s sarcoma has a predilection for 
lower segment of skeleton41. 
 Rhabdomyosarcoma (RMS)  
 Rhabdomyosarcoma arises from various anatomical sites. These tumors 
present as bulging, infiltrative, growing soft tissue masses that may be 
fungating, when they present in external locations such as conjunctiva and 
vagina5.  
Agarwala et al found that most common site of Rhabdomyosarcoma is 
head and neck region followed by genitourinary tract and extremities69.     
Wilm’s Tumor  
Wilm’s tumor presented with abdominal mass, hematuria and pain. 
Hypertension is present in some cases30,38. 
Conditions associated with increased risk of Wilm’s Tumor65 
WAGR syndrome- Wilm’s tumor, aniridia, genito urinary anomalies, 
and mental retardation. 
 Denys –Drash syndrome 
 Familial Wilm’s Tumor 
 Perlman syndrome 
 WT 1 intron 9 splice mutation (Frasier syndrome) 
Beckwith-Wiedemann syndrome 
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 Simpson –Golabi-Behmel syndrome 
 Isolated hemihypertrophy 
 Bloom syndrome 
Trisomy 13, 18 
Neuroblastoma  
Neuroblastoma usually presents with abdominal mass, fever and weight 
loss43. DeLorimer et al, based on California Tumor Registry found that most 
common site of Neuroblastoma was retroperitoneum followed by mediastinum 
and cervical region. About half of the retroperitoneal tumors arise from the 
adrenals17. 
Various clinical presentations of Neuroblastoma3,55 
1. Watery diarrhea (Kerner –Morrison syndrome) 
2. Cushing’s syndrome  
3. Heterochromia iridis & Horner’s syndrome  
4. Opsoclonus / myoclonus – Dancing eye movements  
5. Beckwith – Wiedemann syndrome  
6. Hirschprung’s disease  
7. Hypertension  
8. Blue berry muffin baby – blue red cutaneous metastases   
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Common Metastatic sites of Malignant Round Blue Cell Tumors 
   NHL   - Generalised disease  
Ewing’s sarcoma  - Lungs pleura, skull, Central nervous  
    System, rarely lymph node  
Rhabdomyosarcoma- Soft tissue, serosal surfaces, lungs, 
bone marrow, lymph nodes  
 Wilm’s tumor  - Lungs, liver, peritoneum, Regional  
     lymph nodes    
Neuroblastoma  - Liver (Pepper syndrome) 
     skeletal system, lymphnode, orbit  
  DSRCT  - Liver, pancreas, ovary  
Osteosarcoma  - Bones, Lungs, pleura, heart  
GROSS FEATURES  
   Non Hodgkin’s Lymphomas present with generalized lymphadenopathy 
and hepatosplenomegaly. Nodes are enlarged and have solid homogenous gray 
white appearance38,83.  
 Ewing’s sarcoma / PNET arise in the medullary cavity and transgress the 
cortex and periosteum producing soft tissue masses. The tumor is tan white (or) 
fish flesh like appearance and contains areas of hemorrhage and necrosis38,49.  
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Rhabdomyosarcomas exhibit different gross characters in different sites. 
In body cavities, they present as well circumscribed and multinodular polypoid 
growth with a glistening, gelatinous gray white surface. On cut section they 
show areas of hemorrhage or cystic change. In deep seated sites they are less 
well defined with infiltrative pattern of growth. Cut surface is firm and rubbery 
and have mottled gray white to pink tan appearance74. 
Wilm’s tumors are solitary, well circumscribed, rounded and soft in 
consistency with the cut surface predominantly solid and often exhibiting cystic 
change, hemorrhage and necrosis. Solid areas appear pale gray or tan with 
lobular pattern because of fibrous septation8,38.  
Neuroblastomas are lobulated masses with an average diameter of 6-
8cm. They are surrounded by delicate membranous capsules. Cut surface shows 
soft, fleshy, gray, partially hemorrhagic tumor38,74.  
DSRCTs are solid, large multiobulated masses, on cross section show 
white (or) gray white appearance, with cystic change and necrosis38,77.       
Small cell Osteosarcoma grossly appears similar to that of conventional 
Osteosarcoma and present as bony hard to cystic, friable grayish white tumor 
with areas of hemorrhage22,38. 
 Extra skeletal Mesenchymal Chondrosarcoma presents as a 
multiobulated circumscribed mass of variable size. Cut surface show mixture of 
fleshy gray white soft tissue with irregularly sized cartilage and bony tissue38,74.  
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Methods in the diagnosis of Malignant Round Blue Cell Tumors62 
Table-4 
Light microscopy  
Electron microscopy  
Immunophenotyping (Paraffin sections) 
Immunophenotyping (Monoclonal antibodies, frozen sections) 
Methods using imprints  
 PAS and special stains 
 Immunophenotyping (Polyclonal and monoclonal antibodies) 
 Interphase cytogenetics 
Methods using viable tumor tissue  
 Short term tissue culture  
 Cytogenetics and molecular cytogenetics (FISH) 
 Molecular genetic analysis  
Biochemical analysis  
 Neurotransmitter analysis (Homovanillic acid, vannillyl mandelic acid) 
MICROSCOPIC FEATURES  
 In hematoxylin and eosin sections, diagnosis is by cytoplasmic and 
nuclear features with the pattern of arrangement including the intervening 
stromal cells.  
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NON HODGKINS LYMPHOMA (NHL) 
 Nodal 
 The lymph node structure shows total or partial effacement of 
architecture and composed of monotonus population of small lymphocytes with 
clumped chromatin, inconspicuous nucleoli and scanty cytoplasm38, 77.  
Extra nodal 
        NHL can also be seen in extra nodal sites in relation to mucosae or 
glandular epithelia, such as gastrointestinal tract, salivary glands, lacrimal 
glands, lung, thyroid, conjunctiva, bladder and skin8, 38. 
 EWING’S SARCOMA / PNET  
 The tumor cells are small and uniform with indistinct cell borders 
resulting in a syncytial appearance. The tumor cells have scanty clear 
cytoplasm, round nuclei with frequent indentation and small nucleoli. They are 
arranged in solid sheets, around the blood vessels (Pseudo-rosette) and also as 
true rosettes38, 77. 
EMBRYONAL RHABDOMYOSARCOMA  
    This tumor is characterized by alternating densely packed hypercellular 
and loosely textured myxoid areas. The tumor cells are small round or spindle 
shaped with hyperchromatic nuclei, 1 or 2 nucleoli with indistinct cytoplasm. 
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There are variable amounts of large cells with abundant eosinophilic cytoplasm 
and round vesicular nuclei (Rhabdomyoblast)74.  
BOTRYOID RHABDOMYOSARCOMA  
         This tumor is characterized by a subepithelial condensation of tumor cells 
separated from an intact surface epithelium by a zone of loose stroma 
(Nicholson’s cambium layer)38,74. 
ALVEOLAR RHABDOMYOSARCOMA  
        The tumor cells are small, round to oval cells with scanty cytoplasm and 
round nuclei. The tumor cells are separated into nests by fibrous septa with 
central loss of cohesion and formation of irregular alveolar spaces74. 
WILM’S TUMOR  
 This tumor usually presents with triphasic components and sometimes 
biphasic or monophasic. The triphasic components composed of combinations 
of epithelial, stromal and blastemal elements. Epithelial components are 
characterized by embryonic tubular structures resembling normal developing 
tubules and glomeruli. . Mesenchymal elements are spindle shaped fibroblast 
like cells with a smooth muscle and skeletal muscle differentiation. 
 Blastemal components are cellular areas composed of small round to 
oval primitive cells with scanty cytoplasm, round to oval nuclei, coarse 
chromatin arranged in diffuse sheets and nests38, 77.  
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NEUROBLASTOMA  
 The tumor cells are small and regular with round deeply staining nuclei, 
slightly larger than lymphocytes. There is little cytoplasm with poorly defined 
cytoplasmic borders. The tumor cells are separated into small lobules by 
delicate fibrovascular septa. Homer-Wright rosettes are central fibrillary 
material surrounded by tumor cells and are seen in 1/4 to 1/3 of cases. 
Calcification may appear as a dust like basophilic stippling, as closely 
aggregated round concretions in a “chicken wire” fashion38, 74.  
DESMOPLASTIC SMALL ROUND CELL TUMORS (DSRCTs) 
 DSRCTs composed of sharply outlined islands of tumor cells separated 
by abundant cellular stroma (desmoplastic). The tumor cells are small round, 
monotonus with scanty cytoplasm and hyperchromatic nuclei8, 38.  
SMALL CELL OSTEOSARCOMA  
 The tumor cells are round to spindle shaped with scanty cytoplasm and 
round hyperchromatic nuclei arranged in diffuse sheets with intervening 
neoplastic osteoid22, 38, 49.  
MESENCHMAL CHRONDROSARCOMA  
 Tumor exhibits bimorphic pattern, composed of sheets of 
undifferentiated small, round to oval cells with islands of cartilaginous area. 
The cartilaginous foci are usually well defined with central calcification and 
ossification74.  
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MYXOID CHONDROSARCOMA  
 The tumor cells are round to elongated with uniform size and shape. 
They have deeply eosinophilic cytoplasm and small round hyperchromatic 
nuclei. They are arranged in anastamosing cords, strands and pseudoacinar 
pattern with the intervening stroma composed of mucoid material38, 74.    
POORLY DIFFERENTIATED SYNOVIAL SARCOMA  
 These are highly cellular with numerous mitoses and necrosis. The tumor 
cells are darkly staining ovoid to round cells similar to that seen in other small 
round cell tumors74. 
ROUND CELL LIPOSARCOMA  
 The tumor is characterized by small, round cells with acidophilic 
cytoplasm and round vesicular nuclei arranged in nests, sheets and 
pseudoglandular pattern with typical lipoblasts74.  
MALIGNANT RHABDOID TUMOR  
 The tumor cells are round to oval with eosinophilic cytoplasm and round 
vesicular nuclei arranged in diffuse sheets, alveolar and trabecular pattern. The 
tumor cells have large cytoplasmic, eosinophilic hyaline globules displacing the 
nuclei laterally resulting in a plasmacytoid appearance38, 74.  
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                                CYTOLOGICAL FEATURES 
                                              Table-5 
Features                      Tumor Type  
 Uniform round cells Ewing’s sarcoma, Neuroblastoma, Alveolar 
RMS 
Spindle shaped (or) fusiform cells  Embryonal RMS, Ewing’s Sarcoma /PNET, 
Wilm’s tumor 
Rim of basophilic cytoplasm  Burkitt’s NHL 
Thin rim of clear cytoplasm due to 
prominent glycogen content  
Ewing’s Sarcoma /PNET 
Vacuoles in cytoplasm Burkitt’s NHL 
Convoluted nuclei Lymphoblastic NHL 
Peripheral nucleoli Large cell NHL 
Central prominent nucleoli Immunoblastic NHL 
Thin rim of cytoplasm with glycogen 
positivity  
Rhabdomyosarcoma, Ewing’s Sarcoma 
/PNET  
  
Presence of differentiating cells in the tumor tissue, which give an important 
clue to arrive at a diagnosis.  
a) Ganglion cells: Cells with vesicular nucleus, small nucleolus and 
discernible cytoplasm in Neuroblastoma38, 74.  
b) Rhabdbomyoblasts and strap cells: These are spindle shaped cells with 
eosinophilic cytoplasm, one (or) two centrally placed nuclei, and 
prominent nucleoli with (or) without cross striations. This is one of the 
diagnostic clues for Rhabdomyosarcoma74.  
26 
 
c) Spider cells (or) multivacuolated cells: When the glycogen is removed 
during fixation, it results in large multivacuolated cells with narrow 
strands of cytoplasm connecting the center of the cell with its periphery. 
This is also seen in certain cases of Rhabdomyosarcoma74.    
The centrally located nuclei and the irregular shape of cytoplasmic 
vacuoles help to distinguish these cells from the more rounded lipid filled 
vacuoles of lipoblasts.  
STROMAL CELLS IN SELECTIVE TUMORS  
In certain Malignant Round Blue Cell Tumors, characteristic stromal 
background helps us to arrive at a diagnosis which is tabulated in the Table 
No.-6. 
                                            Table No- 6 
Tumors  Characteristic background  
Neuroblastoma  Neurofibrillary background (Mats of neurophil, 
which are tangled networks of cell processes) 
Ewing’s sarcoma/PNET Bicellular strands of tissue separated by ‘filmy’ 
vascular stroma, referred as ‘filigree’ pattern  
Desmoplastic Small Round 
Cell Tumor (DSRCT) 
Nests of tumor cells surrounded by abundant 
fibrous connective tissue 
Extraskeletal Mesenchymal 
Chondrosarcoma  
Tumor cells admixed with cartilaginous tissue  
Myxoid Chondrosarcoma  Myxoid background  
Small cell Osteosarcoma  Malignant osteoid  
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Radiographic findings in certain Malignant Round Blue Cell Tumors 
NHL    CT examination of the thorax and abdomen is a 
vital element in the assessment of extensions. For 
stage I or II lesions, MRI of the bone marrow,  
liver and spleen are done  to confirm whether the 
lesions are localized12. 
Ewing’s/PNET  This tumor typically presents in diaphyseal or  
    metadiaphyseal region of long bone. The lesion  
    is intramedullary and is associated with cortical  
thickening and cyclical periosteal reaction, giving                             
rise to the characteristic onion –skin appearance12,49. 
Rhabdomyosarcoma  Radiography is done to confirm the presence of  
mass whenever there is clinical suspicion. And it 
may identify calcification and adjacent skeletal 
involvement12. 
Wilms tumor   Intravenous pyelogram shows intrarenal mass that  
displaces and distorts the pelvis. Computed                            
tomography (CT) and Magnetic resonance imaging 
(MRI) are used to define the tumor extent38. 
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Neuroblastoma  - When it occur in the retroperitoneum, causes  
   anterior, lateral and downward displacement of  
   kidney without hydronephrosis. 50% of  
   Neuroblastoma show fine stippled calcification.   
   Radiolabelled Metaiodobenzylguanidine (MIBG) is 
incorporated into catecholamine secreting cells to 
detect bone and soft tissue involvement38.  
Special stains 
 Reticulin stain shows fine branching Reticulin network with pericellular 
fibrils characteristic of Lymphoma29, 37. 
 Ewing’s sarcoma/PNET usually contains large amounts of cytoplasmic 
glycogen which is demonstrated by PAS (Periodic Acid Schiff’s) stain with 
diastase control29, 37,38.  
IMMUNOCYTOCHEMISTRY IN DIAGNOSIS OF MALIGNANT 
ROUND BLUE CELL TUMORS 
The development of sensitive reagents and detection systems, together 
with the introduction of heat-induced antigen retrieval, has rapidly entrenched 
immunohistochemistry as an indispensable adjunct to routine histological 
examination, contributing to diagnosis, prognosis and treatment1. 
  Immunohistochemistry can be helpful in narrowing the differential 
diagnosis of small-round-cell tumors.  
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For example, the cell surface glycoprotein p30/32MIC2 is highly expressed 
in the Ewing family of tumors and also in Rhabdomyosarcoma and Non-
Hodgkin's Lymphoma. Antibodies to desmin can be used to distinguish 
Rhabdomyosarcoma from Ewing's sarcoma, Neuroblastoma, and Lymphoma. 
Similarly, antibodies to leukocyte common antigen (LCA) can be used to 
separate hematolymphoid malignancies from the remainder of small-round-cell 
tumors. Nevertheless, there is no antibody specific for a single tumor type2, 5, 40, 
50,66,72,81.  
Overlaps of mesenchymal, epithelial, and neural markers are present in a 
variety of tumors. Furthermore, reactivity to antibodies can vary depending on 
the preparation of the specimen, the antibody used, and the degree of tumor 
differentiation.  
INITIAL ANTIBODY PANEL13  
Myogenin or Desmin 
NB84 or Neuron specific Enolase 
Leukocyte Common Antigen (LCA-CD 45) 
CD99 
Vimentin  
Cytokeratin 
The immunocytochemical profiles of conventional and extended 
spectrums of Malignant Round Blue Cell Tumors and aberrant 
immunoreactivity of these tumors are presented in Table No.720, 21,42,46,60. 
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ANTIBODIES AND IMMUNOREACTIVITY OF MALIGNANT 
ROUND BLUE CELL TUMORS10,13,26,29,38,49,77 
Table No-8 
Antibody Tumors Typically Immunoreact with Antibody Tumors may Immunoreact with Antibody 
Leukocyte common Antigen  Lymphoma Mesenchymal Chondrosarcoma 
S-100 Protein Neuroblastoma, MPNST 
Ewing’s sarcoma /PNET 
DSRCT, Hepatoblastoma, Wilms Tumor, 
Synovial sarcoma, Rhabdomyosarcoma 
Myofibroma, Mesenchymal 
Chondrosarcoma, small cell Osteosarcoma 
NB84 Neuroblastoma DSRCTs, Ewing’s sarcoma 
Neuron specific Enolase Neuroblastoma, DSRCT Rhabdomyosarcoma, Ewing’s sarcoma 
Myogenin Rhabdomyosarcoma DSRCTs, Wilm’s Tumor 
Desmin Rhabdomyosarcoma, DSRCT Wilm’s Tumor / MPNST, Rhabdoid Tumor 
Muscle specific Actin Rhabdomyosarcoma DSRCTs, Wilm’s tumor, Rhabdoid tumor, 
MPNST 
CD99 Ewing’s Sarcoma /PNET Leukemia, Lymphoma, RMS, DSRCTs, 
Synovial sarcoma, Mesenchymal 
Chondrosarcoma 
Pancytokeratin Synovial sarcoma, 
Hepatoblastoma, Carcinoma, 
Rhabdoid Tumor, Germ cell 
tumors, DSRCT 
Ewing’s sarcoma, RMS, Leukemia, 
lymphoma 
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Antibody panels for defining origin of undifferentiated Malignant 
Round Blue Cell Tumors8, 13, 38, 77 
Myogenic:  Desmin 
  Myogenin 
   Muscle Specific Actin 
Neural:  Chromogranin  
NB84 
   Neuron specific enolase 
   S100 
Lymphoid:     Leukocyte Common Antigen 
   Myeloperoxidase protein 
Germ Cell:  Alpha fetoprotein 
   Pancytokeratin 
Neural Crest:  S100 Protein 
   HMB-45 
CD99 
Mesenchymal: Vimentin 
Smooth muscle Actin 
ELECTRON MICROSCOPIC FEATURES OF MALIGNANT         
ROUND BLUE CELL TUMORS,  
Triche et al commented that "Overall, electron microscopy is probably 
the most universally useful of all diagnostic techniques other than light 
microscopy in round cell tumors." With these tumors, electron microscopy 
demonstrated itself to be more reliable than immunohistochemistry.  
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Electron microscopy offers not only greater sensitivity and specificity, 
but also greater versatility. The concept of replacing electron microscopy with a 
battery of immunostains has often been advocated as an economic 
measure26,27,33,52,54, 
Electron microscopic findings of certain tumors are tabulated in Table 
No-9 
                                                 Table No-9 
Tumor type 
Cytoplasmic
Glycogen 
Basal 
lamina
Intercellular 
junctions 
Myofilament 
Neurosecretory 
granules 
Ewing’s sarcoma/ 
PNET 
+ -- + -- + 
Rhabdomyosarcoma + + -- + -- 
Neuroblastoma -- -- + -- + 
NHL -- -- -- -- -- 
Presence of neurosecretory granules in Ewing’s sarcoma/PNET favours 
neuronal differentiation16,38,74  
       Alternative thin and thick bands of myofilaments are diagnostic of 
Rhabdomyosarcoma74. 
Wilm’s tumor shows triphasic components. Blastemal components have 
junctional complexes similar to other epithelial cells. A definite basement 
membrane was absent but numerous mitochondria, lipid droplets, granular 
endoplasmic reticulum and Golgi vesicles seen85. 
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MOLECULAR PATHOLOGY OF MALIGNANT ROUND BLUE 
CELL TUMORS 
            Molecular markers have been increasingly used as a diagnostic tool as 
well as indicators for prognosis. However, accurate karyotyping of solid tumors 
is technically difficult, and successful cytogenetic analysis can be performed in 
only a subset of cases81,. Despite the technical limitations, detection of a 
cytogenetic abnormality can be an important diagnostic aid in some childhood 
cancers68. For example, the t (11; 22)(q24;q12) translocation is frequently seen 
in the Ewing family of tumors, which includes Ewing's sarcoma, peripheral 
neuroectodermal tumors (PNET), and Askin's tumor. However, this 
translocation is not specific for the Ewing's family of tumors64,58. 
 Recent studies have demonstrated that the t(11;22) (q24;q12) 
translocation can be identified in some of the cases of Neuroblastoma and 
Rhabdomyosarcoma. Molecular markers that are used to diagnose Malignant 
Round Blue Cell Tumors are shown in Table No.109,34,44 
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MOLECULAR MARKERS USED IN DIAGNOSIS & PROGNOSIS            
OF MALIGNANT ROUND BLUECELL TUMORS 
                                                 Table No-10 
Tumor Marker 
Locus/Transl
ocation 
Comments/Techniques 
NB MYCN 2p24 
Amplification (> 10 copies), poor 
prognosis, usually associated with high 
stage disease; PCR or southern blot. 
NB Del 1p 1p3l-1p32 
Associated with high stage disease; smaller 
deletion associated with more favourable 
outcome; PCR 
ES/PNET EWS/FLI-1 
(11,22)(q24; 
q12) 
Found in up to 90% cases; Types I and II 
fusion products most common; Type I 
more favourable; RT-PCR 
ES/PNET EWS/ERG 
(21,22)(q22:q
21) 
 
Found in up to 5% of cases; RT-PCR 
NHL, B-Cell 
type 
IgH 14q32 
Gene rearrangements identified in > 90% 
of cases; PCR or southern blot 
NHL, T-Cell 
type 
TCR or 7q34 or 7p15 
Rearrangements identified in majority of 
cases; PCR or Southern blot 
Wilms Tumor WT1 11p13 
Mutations occur in both sporadic and 
hereditary Wilms Tumors; PCR 
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Tumor Marker 
Locus/Transl
ocation 
Comments/Techniques 
DSRCT EWS/WT-1 
(11,22) (q113; 
q12) 
Only found in DSRCT; RT-PCR 
Alveolar 
Rhabdomyosarc
oma 
PAX3/FKHR 
(2; 13)(Q35; 
q14) 
Found in up to 70% of cases; 20% cases 
have t(1;13)(p36;q14), PAX7/FKHR 
associated with better prognosis; RT-PCR 
Synovial 
sarcoma SYT/SSX 
(X:18)(P11:Q
11) 
80% of cases; SYT/SSX1 in biphasic 
sarcomas. SYT/SSX2 in monophasic type 
associated with better prognosis: RT-PCR 
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MATERIALS AND METHODS 
The present study had been carried out in the Department of Pathology, 
Madurai Medical College, Madurai for a period of 2 years from June 2008 to 
May 2010. The specimens were received from Government Rajaji Hospital and 
Meenakshi Mission Hospital which cater the health need of the people in and 
around Madurai. 
The clinical details of the patients such as age, sex, symptoms, status of 
liver, spleen, peripheral smear findings and radiological findings were recorded 
with the informed consent. The working proforma was appended in annexure I. 
 The histopathology specimens were fixed in 10% formalin.The entire 
small biopsy specimens received were embedded. In large specimens, the gross 
characterstic of the tumor such as size, shape, cut surface, hemorrhage and 
necrosis were noted. Adequate bits were taken from different areas of the 
specimen. The tissues were processed, paraffin blocked, 5 micron thin sections 
were cut and stained with Hematoxylin and Eosin (H &E). Special stains such 
as PAS (Periodic Acid Schiff’s) and Reticulin were used as and when required. 
Immunohistochemical studies were done in relevant cases. The procedures are 
shown in Appendix –II. Photographs of the specimen and photomicrographs of 
the slides were taken whenever needed.  
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The results of histopathological study of H&E stained sections, special 
stains and Immunohistochemical results were entered in the proforma and 
master chart (Annexure IV). The Immunohistochemical marker study had 
enabled to categorize the Malignant Round Blue Cell Tumors and helped to 
achieve a more accurate and precise diagnosis there by aiding the clinicians for 
the management of these patients by more specific therapeutic protocols.    
Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2008) developed by Center for 
Disease Control, Atlanta. Using this software, frequencies, percentages, means 
and standard deviations were calculated. 
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OBSERVATION AND RESULTS 
 In the two year study period from June 2008 to May 2010, specimens 
were received for histopathological examination from Government Rajaji 
Hospital and Meenakshi Mission Hospital, Madurai.  
Out of 17,782 cases from Government Rajaji Hospital 2826 were 
reported as malignant lesions and out of 7853 cases from Meenakshi Mission 
Hospital 2210 were reported as malignant lesions. Altogether 70 cases had been 
reported as Malignant Round Blue Cell Tumor with the incidence of 1.38 %.  
ChartNo.1 
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Among the 70 cases of Malignant Round Blue Cell Tumors studied, Non 
Hodgkin’s Lymphoma was diagnosed in 36 (51.5%) cases, Ewing’s 
sarcoma/PNET in 10 (14.5%) cases, Wilm’s tumor and Rhabdomyosarcoma 
each in 7 (10% + 10%) cases and Neuroblastoma in 5 (7%) cases. The 
distributions of Malignant Round Blue Cell Tumors were represented by Chart 
No.1 and Table No.11.  
                 Table No.11 Histopathological Diagnosis 
Tumor type  No. of cases  Percentage (%) 
Non Hodgkin’s lymphoma  36 51.5 
Ewing’s sarcoma / PNET 10 14.5 
Rhabdomyosarcoma 7 10 
Wilm’s tumor 7 10 
Neuroblastoma  5 7 
Desmoplastic Small Round Cell tumor 1 1.4 
Small cell Osteosarcoma  1 1.4 
Extraskeletal Mesenchymal 
Chondrosarcoma 
1 1.4 
Undifferentiated Malignant Round Blue 
Cell Tumor (MRBCT) 
2 2.8 
Total 70 100 
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Age incidence 
The mean age at diagnosis of Malignant Round Blue Cell Tumors has 
been tabulated in Table No 12. 
Table No.12 : Mean Age at Diagnosis of Malignant Round Blue Cell 
Tumors 
 
HPE Diagnosis 
Age in years 
Mean 
Standard 
Deviation 
NHL (36) 44.9 23 
Ewing’s Sarcoma (10) 21.3 12.9 
Rhabdomyosarcoma (7) 16.9 12.3 
Wilm’s Tumour (7) 4.5 4.4 
Neuroblastoma (5) 13.9 21.3 
Malignant round blue cell tumour (2) 
(Undifferentiated)  
30.3 39.2 
Others(3) 12.8 12.9 
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Non Hodgkin’s Lymphoma was diagnosed in youngest age of 4 years 
and oldest age of 92 years. 
            Ewing’s sarcoma/PNET was diagnosed at the youngest age of 8 years 
and oldest age of 48 years.  
             Embryonal Rhabdomyosarcoma was diagnosed at the youngest age of 3 
months and oldest age of 21 years.  
 Wilm’s tumor was diagnosed at the youngest age of 6 months and oldest 
age of 12 years.  
 Neuroblastoma was diagnosed at the youngest age of 3 years and oldest 
age of 52 years.  
 Among the 36 cases of Non Hodgkin’s lymphoma, 5 cases were 
diagnosed in pediatric population and the rest 31 cases in adult population 
especially in patients above 40 years.  
            Out of 10 cases of Ewing’s sarcoma /PNET studied, 1 case was 
diagnosed in 8 year old child and rest of the cases were diagnosed in adolescent 
and adult age group.  
All the 7 Wilm’s tumor cases were diagnosed in children only. All cases 
of Neuroblastoma occurred in children except one in adult.  
 4 cases of Embryonal Rhabdomyosarcoma were seen in children and the 
rest 3 in adults. 
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 The age incidence of Malignant Round Blue Cell Tumors ranges from 3 
months to 92 years in this study. The age incidences of Malignant Round Blue 
Cell Tumors are shown in Table No 13 and Chart No 2 
 
Malignant Round Blue Cell Tumors in Children versus Adults 
Table No -13 
Tumor Type 
Cases 
Children Adults 
No. % No. % 
Non Hodgkin’s Lymphoma (36) 5 13.9 31 86.1 
Ewing’s Sarcoma(10) 1 10 9 90 
Rhabdomyosarcoma (7) 4 57.1 3 42.9 
Wilm’s tumor(7) 7 100 - - 
Neuroblastoma(5) 4 80 1 20 
Undifferentiated Malignant Round Blue Cell 
Tumors (2) 
1 50 1 50 
Others(3) 1 33.3 2 66.7 
Total (70) 23 32.9 47 67.1 
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Chart No .2 
 
 
It is observed from the study that Malignant Round Blue Cell Tumors 
are commonly seen in paediatric age group except Non Hodgkin’s Lymphoma 
which is common in adults 
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Sex Incidence  
 Out of the 70 cases of Malignant Round Blue Cell Tumors, 45 cases 
occurred in males and 25 cases in females with the male to female ratio of 
(1.8:1) as illustrated in the Chart No 3. 
 
 
 
 
Chart No -3 
 
 
The incidence of various tumor types according to sex had been depicted 
in Table No-14 and Chart No-4. Non Hodgkin’s Lymphoma predominantly 
occurred in males with the male to female ratio of 2.3:1.  
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Sex incidence of individual tumor type 
Table No-14 
HPE Diagnosis  
Sex 
Male Female 
No. % No. % 
Non Hodgkin’s Lymphoma (36) 25 69.4 11 30.6 
Ewing’s Sarcoma(10) 7 70 3 30 
Rhabdomyosarcoma (7) 4 57.1 3 42.9 
Wilm’s tumor(7) 4 57.1 3 42.9 
Neuroblastoma(5) 1 20 4 80 
Undifferentiated Malignant Round 
Blue Cell Tumor (2) 
2 100 - - 
Others(3) 2 63.3 1 33.7 
Total (70) 45 64.3 25 35.7 
 
The three tumors, Ewing’s sarcoma / PNET, Wilm’s tumor and 
Rhabdomyosarcoma had a male predominance with the male to female ratio of 
2.3:1, 1.3:1 and 1.3:1 respectively, whereas Neuroblastoma had a female 
preponderance with the male to female ratio of 1:4. 
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Chart No.4 
 
 
It was observed that the Malignant Round Blue Cell Tumors were 
common in males than females in this study.  
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CLINICAL PRESENTATION  
Non Hodgkin’s Lymphoma (NHL) 
Non Hodgkin’s lymphoma was reported in the Nodal (Fig1,2,3) as well 
as the extra nodal(Fig5,9,13) sites. 26 cases of nodal Non Hodgkin’s lymphoma 
presented with generalised lymphadenopathy and one case had leukemic 
dissemination as represented in Table No-15 and Chart No -5. 
 
Clinical Presentation of Nodal Non Hodgkin’s Lymphoma 
Table No-15 
Clinical Presentation No. of cases Percentage (%) 
Lymphadenopathy 26 100 
Hepatomegaly 1 3.8 
Spleenomegaly 2 7.7 
Abdominal mass 7 26.9 
Mediastinal mass 14 53.8 
Leukemic dissemination 1 3.8 
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Chart No: 5 
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10 cases of Non Hodgkin’s Lymphoma occurred in different extra nodal 
sites (Fig 6,10,14) with varied clinical presentation depending upon the site of 
involvement which is shown in the (Table No. 16). 
 
Table No-16 
 
Malignant Round Blue Cell Tumors other than NHL 
         These tumors presented as bony and soft tissue mass in various sites. 
 
 
S.No Site No of cases Clinical presentation 
1 Parotid 2 Swelling in the parotid 
region 
2 Stomach 3 Epigastric  mass 
3 Ileum & Colon 2 Right iliac fossa mass 
4 Testis 1 Swelling in the scrotum 
5 Tibia 1 Swelling above  the ankle 
joint 
6 Nasopharynx 1 Dysphagia & Swelling in the 
neck 
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Ewing’s sarcoma / PNET 
Out of 10 cases of Ewing’s sarcoma / PNET (Fig 15), 7 were observed in 
lower segment of the skeleton and the rest 3 in upper segment. The Table No 17 
showed various anatomical distribution of these tumors.  
Anatomical distribution of Ewing’s sarcoma  
Table No: 17 
S.No. No. of cases 
Anatomical distribution  
Bone Soft tissue 
1 1 Iliac bone - 
2 3 Tibia  - 
3 2 Femur  - 
4 1 Fibula - 
5 1 - Elbow 
6 1 - Chest wall 
7 1 - Axillary region  
  
    Wilm’s tumor  
 All the 7 cases presented with abdominal mass and were unilateral. 
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Rhabdomyosarcoma 
The study revealed that Rhabdomyosarcoma (Fig 19) occurred mainly in 
Head and Neck region and also in other sites such as genitourinary tract and 
extremities as illustrated in Table No 18 
Anatomic distribution of Rhabdomyosarcoma  
Table No: 18 
S.No. No. of cases  Clinical presentation 
1 2 Extremity  
2 2 Nasopharynx  
3 2 Genitourinary region 
4 1 Eye ball 
 
Neuroblastoma 
The study showed that Neuroblastoma(Fig29,30) most commonly 
presented as retroperitoneal mass rarely as presacral and nasal mass as shown in 
TableNo19. 
Anatomic distribution of Neuroblastoma –Table No: 19 
 
S.No. No. of cases Clinical presentation 
1 3 Retroperitoneal mass 
2 1 Presacral mass 
3 1 Nasal mass 
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Histopathology 
70 cases of Malignant Round Blue Cell Tumors were taken for the study. 
All the sections were stained with hematoxylin and eosin (H & E) stain. Special 
stains such as Reticulin and PAS were done in relevant cases. 
Immunohistochemical marker study was also done in selective cases. 
Hematoxylin and Eosin (H & E) 
The sections stained with H&E were studied under light microscopy and 
the diagnosis was made based on the cellular morphology such as cytoplasmic 
and nuclear features, intervening stroma and pattern of arrangement of tumor 
cells. 
          The microscopic study showed 34 cases as NHL and 36 cases as 
Malignant Round Blue Cell Tumors other than NHL. Out of the 34 cases of 
NHL, 26 occurred in the nodal and the rest 8 in extranodal sites (Fig 7,11,14). 
Among the 36 cases of Malignant Round Blue Cell Tumors other than 
Non Hodgkin’s Lymphoma constituted   8 cases of Rhabdomyosarcoma, 7 
cases of Wilm’s tumor (Fig 25,26,27) , 6 cases of Ewing’s sarcoma / PNET and 
5 cases of Neuroblastoma. The study also showed one case in each of small cell 
Osteosarcoma(Fig32), Extra skeletal Mesenchymal Chondrosarcoma(Fig31) 
and Desmoplastic Small Round Cell Tumor (DSRCT)(Fig 33). Rest of the cases 
didn’t fit into any of the specific type and were categorized as Undifferentiated  
Malignant Round Blue Cell Tumors. 
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Special stains 
Special stains such as Reticulin and Periodic Acid Schiff’s (PAS) were 
done in selective cases.  Reticulin stain (Fig 4) was done for all the cases of 
nodal NHL which showed fine branching reticulin network with pericellular 
fibrils characteristic of Lymphoma. PAS stain (Fig 16) was done for 6 cases of 
Ewing’s sarcoma/PNET, which demonstrated abundant cytoplasmic glycogen 
positivity. 
Immunohistochemistry (IHC) 
Immunohistochemical marker study was done for all the cases of    extra 
nodal NHL. Specific IHC marker study was done in randomly selected cases to 
confirm the   H &E diagnosis. Panel of IHC marker study was done for all the 
cases of Undifferentiated Malignant Round Blue Cell Tumors as illustrated in 
Table No 20. 
IHC marker study such as CD 45(Leukocyte common antigen-LCA) 
(Fig 8,12) was done for all the cases of extra nodal NHL, which showed 
membranous positivity thus confirming the H&E diagnosis. In addition 
cytokeratin was also done for gastro intestinal NHL to rule out the possibility of 
poorly differentiated carcinoma by its negative reaction. 
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 Specific IHC marker study was done for randomly selected 8 cases of 
Malignant Round Blue Cell Tumors for further evaluation and confirmation. 
The study confirmed a case of Ewing’s sarcoma/ PNET by its membranous 
positivity for CD99 (Fig17) and positivity for vimentin (Fig18). Two of the 
Wilm’s Tumor cases were confirmed with vimentin (Fig 28) positivity both in 
blastemal and stromal cells Neuroblastoma was confirmed with positivity for 
chromogranin (Fig 30) and S-100 in 3 of the cases.  
Among the Rhabdomyosarcoma (Fig 20) cases subjected to IHC marker 
study, one was confirmed with desmin (Fig 21) positivity and another showed 
negativity for desmin. Hence this case was included in the Undifferentiated 
Malignant Round Blue Cell Tumors category and subjected to panel of IHC 
marker study. 
Panel of IHC marker study was done for all the Undifferentiated 
Malignant Round Blue Cell Tumors. Vimentin and CD 99 were positive in 4 
cases and proved to be Ewing’s sarcoma /PNET. Two cases showed CD 45 
positivity and were included in extranodal Non Hodgkin’s Lymphoma category. 
The rest two cases (Fig 34) showed negativity for all the IHC markers in the 
primary antibody panel. The final results were tabulated in the Table No- 21. 
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The histopathological diagnosis based on H&E sections categorized the 
70 cases of Malignant Round Blue Cell Tumors into 34 cases of NHL (26 
nodal+ 8 extranodal) and 36 cases of Malignant Round Blue Cell Tumors other 
than NHL.  
Among the 36 cases of Malignant Round Blue Cell Tumors other than 
NHL 2 cases had been diagnosed as NHL by Immunohistochemical marker 
study, thereby making a total of NHL as 36 cases. Two cases remained in the 
undifferentiated category even after Immunohistochemistry.  
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DISCUSSION 
 Malignant Round Blue Cell Tumors comprise a diverse group of 
diagnostically challenging primitive and undifferentiated neoplasms.  Although 
classical histological features are highly suggestive of a tumor type, on occasion 
these tumors are indistinguishable by light microscopy, making a definitive 
diagnosis difficult. Accurate diagnosis of Malignant Round Blue Cell Tumors 
has become increasingly crucial, as disparate approaches to therapy are used for 
distinct tumor types.  
Incidence  
The incidence of Malignant Round Blue Cell Tumors in the present 
study is 1.38%. The 70 cases of Malignant Round Blue Cell Tumors were 
categorized into 36 cases of Non Hodgkin’s Lymphoma (NHL) and 34 cases of 
Malignant Round Blue Cell Tumors other than NHL.  
Non Hodgkin’s lymphoma is the most common tumor, constituting 36 
cases (51.5%). Ewing’s sarcoma / PNET constitute 10 cases (14.5%).Wilms 
tumor and Rhabdomyosarcoma each constitute 7 cases (10%+10%). 
Neuroblastoma constitutes 5 cases (7%).  
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Age  
In this present study, the age of the patients with Malignant Round Blue 
Cell Tumors ranged between 3 months to 92 years, 23 cases in children with 
32.9% of incidence and 47 cases in adults with 67.1% of incidence. 
 NHL is common in adults than in children with ratio of 4:1.The mean 
age at diagnosis of NHL is 44.9 years. Surveillance Epidemiology and End 
Results80 (National Cancer Institute.USA) showed 67 years as the median age at 
diagnosis of NHL.  
 Ewing’s/PNET is predominantly seen in adolescent age group, which is 
similar to the study conducted by Carvajal R et al6 in which common age group 
for Ewing’s sarcoma / PNET is 10-20 years.         
 In the present study, Rhabdomyosarcoma (RMS)(Fig 22,23) is common 
in children than adults. Most of the RMS cases are below 21 years with the 
mean age at diagnosis of 16.9 years. This study correlates well with the study 
conducted by Michael et al51 who also found that RMS occurred commonly in 
patients younger than 21 years. 
This current study showed median age at diagnosis of Wilm’s tumor as 
53 months (4.5 years). Mir Mahmood Seyed Ahadi et al55 found that mean age 
at the time of diagnosis as 45.2 months (4years) which is slightly lower than 
that found in the present study. Norman Breslow et al57 found that median age 
at diagnosis of Wilm’s tumor is 39.5 months. 
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In this study, 80% cases of Neuroblastoma are seen under the age of 6 
correlating with the study conducted by Stiller C A et al79 which also showed 
80% of cases below the age of 4. 
Sex  
In the present study Malignant Round Blue Cell Tumors show a male: 
female ratio of 1.8:1.  
This study shows a male preponderance of Non Hodgkin’s lymphoma 
with a male: female ratio of 2.2:1, which correlates with the Surveillance 
Epidemiology and End Results80 (National Cancer Institute.USA) which also 
shows a male preponderance with a male: female ratio of 1.4:1. 
Carvajal R et al6 found slight male predominance of Ewing’s sarcoma/ 
PNET. This current study correlates with the above study with a male: female 
ratio of 2.3:1. 
Simona Ognjanovic et al76 found a male preponderance for 
Rhabdomyosarcoma with a male: female ratio of 1.37:1.This present study also 
shows a male preponderance with the male: female ratio of 1.3:1. 
Mir Mahmood Seyed Ahadi et al55 found that Wilm’s tumor is common 
in males with a male: female ratio being 1.2:1. This present study correlates 
with the above study with a male: female ratio of 1.3:1.  
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Norman Breslow et al57 found that slight preponderance of females in the 
National Wilm’s tumor study registered between October 1969 and December 
1985. 
Gregory Hale et al28 found a male preponderance in Neuroblastoma with 
a male to female ratio of 1.3:1. In contrast, this present study shows distinct 
female preponderance with the male: female ratio being 1:4.  
Site 
In this study, extra nodal NHL constitutes about 27% of the total NHL 
cases recorded. This can be compared with Antoria M.S.Muller et al4 who 
found that extra nodal NHL constitutes 20-30% of all NHL in his study. 
Sandeep Agarwala et al69 found that most common site of occurrence of 
Rhabdomyosarcoma is the head and neck region. This present study correlates 
with the above study. 
Kissane et al41 found that Ewing’s sarcoma has a predilection for lower 
segment of skeleton as this current study. 
Neuroblastoma commonly present as retroperitoneal mass which 
correlates with the study conducted by DeLorimer et al17 based on California 
Tumor Registry.  
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ROLE OF SPECIAL STAIN  
Reticulin stain was done for all the cases of nodal lymphoma to confirm 
the effacement of architecture, which is characteristic of Lymphoma.  
PAS stain was done to confirm for all the cases of the Ewing 
sarcoma/PNET to confirm the presence of glycogen in the cytoplasm. Although 
these two special stains are not specific for the diagnosis they had a limited role 
in categorizing the Malignant Round Blue Cell Tumors (MRBCT).   
ROLE OF IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) must be interpretated in the context of 
light microscopic findings. In most of the cases, the combination of clinical and 
radiographic findings with light microscopic appearance is sufficient for the 
diagnosis. The decision about when to order immunohistochemistry depends 
upon the complexity of the tumor and the pathologist’s experience. 
Beginning with the limited antibody panel, helps to refine the differential 
diagnosis and allows a more systematic use of financial and tissue resources. 
The panel used depends upon the laboratory resources and capabilities. If 
results are unexpected (or) contradictory, another more comprehensive panel 
may be used. The use of panel of IHC markers rather than over-reliance on a 
single antibody is an important diagnostic principle.  
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Immunohistochemistry   was done for all the cases of extra nodal NHL. 
All these tumors show membranous positivity of CD45 (Leukocyte Common 
Antigen-LCA). Cytokeratin was done for gastro intestinal NHL which showed 
negative reaction thus ruling out the possibility of poorly differentiated 
carcinoma. So the accurate diagnosis was arrived for extra nodal NHL, which 
helped the patients to get a specific treatment.  
Immunohistochemical marker study was also done for few randomly 
selected cases of Malignant Round Blue Cell Tumors other than NHL to 
confirm the H&E diagnosis. The results are shown in the Table No-22 
                                         Table No-22 
 
*This case was included in Undifferentiated Malignant Round Blue Cell 
Tumors and subjected to panel of IHC marker study. 
 
S.No Diagnosis based on H &E No of cases IHC marker 
1 Ewing’s sarcoma /PNET 1 CD 99+ 
2 Wilm’s tumor 2 Vimentin + 
3 Neuroblastoma 3 Chromogranin + 
4 Rhabdomyosarcoma 2 Desmin + in 1 case 
Desmin - in 1 case* 
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The H&E diagnosis very well correlated with the IHC marker study in 
all the cases except one. This case was diagnosed as Rhabdomyosarcoma in 
H&E sections which showed negative reaction for desmin. Hence it is included 
in the undifferentiated category, which later on proved to be Non Hodgkin’s 
Lymphoma by its CD 45 positivity. 
In undifferentiated Malignant Round Blue Cell Tumors, 4 cases showed 
membranous positivity for CD 99 and diffuse positivity for vimentin which 
helped to arrive at a specific diagnosis of Ewing’s sarcoma/ PNET. The close 
differential diagnosis for Ewing’s sarcoma/ PNET is Rhabdomyosarcoma, 
Lymphoma and small cell Osteosarcoma. 
 In the panel of IHC marker (Table No-20) study, negative reaction for 
desmin and CD 45 helped to exclude the Rhabdomyosarcoma and Lymphoma 
respectively, whereas the small cell Osteosarcoma is ruled out due to the 
absence of neoplastic osteoid in H&E sections. 
One of the undifferentiated Malignant Round Blue Cell Tumors arising 
from the bone showed negative reaction for CD 99 and membranous positive 
reaction for CD 45. Hence this is included in the extra nodal NHL category.  
Most of the Malignant Round Blue Cell Tumors are categorized into 
specific types which enables the patients to get appropriate treatment according 
to the final diagnosis. 
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Two of the undifferentiated Malignant Round Blue Cell Tumors showed 
negative reaction for all the IHC markers in the primary antibody panel and 
doesn’t fit into any of the specific category. So these two cases still remain in 
the category of Undifferentiated Malignant Round Blue Cell Tumors. 
For evaluating these two cases, a more comprehensive panel of IHC 
markers may be employed to achieve a specific diagnosis. Techniques such as 
electron microscopy or molecular testing may be necessary to make a diagnosis 
in these cases. Even though IHC marker study is a valuable tool, but it has 
significant pitfalls in certain instances, such as inadequate fixation, over 
fixation, incomplete dehydration during processing or if the paraffin is too hot. 
These are the instances where antigen may be lost from the tissue and these 
technical factors are to be considered while interpreting IHC marker study.  
For making the diagnosis of Malignant Round Blue Cell Tumors, the 
combination of clinical history, radiologic features and light microscopic 
appearance are sufficient in majority of patients. Immunohistochemistry can be 
employed wherever there is difficulty in making the diagnosis by H&E 
sections. The availability of more specific and more sensitive IHC markers has 
enabled to categorize these Malignant Round Blue Cell Tumors. Therapeutic 
modality varies with the individual tumor. So an exact diagnosis of Malignant 
Round Blue Cell Tumor is essential to enable the patients to get an appropriate 
management. 
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SUMMARY 
1. This study was conducted in Madurai Medical College, Madurai from 
June 2008 to May 2010 with the materials received from Government 
Rajaji Hospital and Meenakshi Mission Hospital, Madurai during this 
period. 
2. Among the 5036 malignant lesions, Malignant Round Blue Cell Tumors 
constitute about 70 cases with an incidence of 1.38%. 
3. Non Hodgkin’s Lymphoma (NHL) is the most common type of tumor in 
this study which is about 51.5% (36 cases) and Malignant Round Blue 
Cell Tumors other than NHL constitute 48.5% (34 cases). 
4. Extra nodal Non Hodgkin’s Lymphoma constitutes about 27% of all the 
cases of NHL. 
5. Malignant Round Blue Cell Tumors   other than NHL is common in 
children and adolescence whereas NHL is common in the older age 
group. 
6. Malignant Round Blue Cell Tumors have a male preponderance with a 
male to female ratio of 1.8:1, except in Neuroblastoma which is common 
in females. 
7. The common clinical presentation of NHL is lymph nodal enlargement 
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8. Ewing’s sarcoma/PNET affects lower segment of the skeleton whereas 
Rhabdomyosarcoma involves the head and neck region. Neuroblastoma 
usually presents as retroperitoneal mass. 
9. Reticulin and PAS stains are supportive to the diagnosis of NHL and   
Ewing’s sarcoma /PNET respectively in the study. 
10. The Immunohistochemistry has confirmed hematoxylin and eosin 
(H&E) based diagnosis in most of the cases. 
11. The undifferentiated Malignant Round Blue Cell Tumors are categorized 
into specific types by Immunohistochemical marker study in most of the 
cases.     
12. Specific diagnosis of the Malignant Round Blue Cell Tumors by 
immunohistochemical marker study enabled the patients to get 
appropriate treatment. 
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CONCLUSION 
            Malignant Round Blue Cell Tumors comprise a wide range of 
neoplasms varying considerably in regard to etiology, site of origin, 
involvement of skeletal system and prognosis. But on light microscopy, these 
tumors have the basic morphologic themes of small round blue cells. In the 
diagnosis of Malignant Round Blue Cell Tumors, clinical history, radiologic 
features, light microscopic findings and results of Immunohistochemistry are all 
taken into consideration. Immunohistochemical marker study has a great role of 
categorizing these tumors and accurate diagnosis is made possible which enable 
the patients to get the appropriate treatment. 
 
  
 
ANNEXURE – I  
PROFORMA 
Name      : 
Age / Sex     : 
IP No.     : 
Address    :    
 
Complaints     : 
H/o Present Illness    : 
Family H/o    : 
General Examination   : 
Nutrition  
Stature 
Pallor  
Jaundice 
Hepatomegaly 
Spleenomegaly  
Lymphadenopathy 
Mediastinal Mass 
Abdominal Mass 
Peripheral Smear Examination :   
Radiological Examination   : 
Biochemical Examination   : 
Blood    : 
Urine     : 
Morbid Anatomy   : 
Macroscopy    : 
Microscopy   : 
H&E    : 
Special Stains   : 
Diagnosis    
Immunohistochemistry  : 
Miscellaneous   : 
Final Diagnosis   :    
ANNEXURE - II 
PROCEDURES 
HEMATOXYLIN AND EOSIN29,37 
1. Deparaffinize sections, hydrate through graded alcohols to water. 
2. Stain in Ehrlich’s Hematoxylin for 30 minutes 
3. Wash well in tap water 
4. Differentiate in 1% acid alcohol 
5. Wash well in tap water until sections are again blue for 10-15 minutes 
6. Stain in 1% eosin for 1 to 2 minutes 
7. Wash in running tap water for 1 to 5 minutes 
8. Dehydrate the alcohols clearly in Xylol and mount in DPX. 
 
 
SPECIAL STAINS29,37 
Periodic Acid Schiff’s Stain (Glycogen in ES/PNET) 
Method: 
1. Dewax sections and bring to distilled water 
2. Treat with periodic acid for 5 minutes 
3. Wash well with several changes of distilled water 
4. Cover with Schiff’s solution for 15 minutes 
5. Wash in running tap water 5-10 minutes 
6. Stain nuclei with Harris Hematoxylin. Differentiate as appropriate 
in acid alcohol and blueing in tap water for 5 minutes. 
7. Wash in water 
8. Rinse in absolute alcohol 
9. Clear in Xylene and mount with DPX 
RESULTS 
Glycogen :  Magenta 
Nuclei  : Blue 
 
 
I. RETICULIN STAIN29,37 
 
1. Bring sections to water. 
2. Treat with potassium permanganate solution for 1-2 minutes. 
3. Wash in water, bleach with the potassium metabisulphite solution.  
Wash well in water.  
4. Treat with the iron alum solution for 1 minute. Wash well in tap 
and then distilled water. 
5. Treat with ammoniacal silver solution for 1 minute. 
6. Wash briefly in distilled water and reduce in 10%formalin for 3 
minutes. 
7. Wash, then tone in 0.2% gold chloride for up to 10 minutes. 
8. Rinse in distilled water, then treat with the potassium 
metabisulphite      solution for 1minute. 
9. Rinse with distilled water and fix with 5% hypo for 1-2 minutes. 
10. Wash, dehydrate, clear, and mount in DPX.. 
 
Results:  
 
Reticulin fibers         ……………         Black 
            Nuclei                       ……………         grey  
            Collagen                   ……………         grey-purple 
 
 
 
 
IMMUNO HISTOCHEMICAL STAINING 29,37 
1. Sections to alcohol. 
2. Block endogenous peroxidase activity by incubating in hydrogen 
peroxide solution for 30 minutes. 
3. Hydrate sections by passing through graded ethanol series and wash 
in running water for 15 minutes. 
4. Incubate sections in the normal swine serum diluted in Tris/saline 
for 15 minutes.  
5. Drain off excess Tris-buffered normal swine serum. 
6. Incubate sections with primary antiserum diluted 1:2000, 1:1000, 
1:250 and 1:100 in 1%normal swine serum for 30 minutes. 
7. Jet wash off excess antiserum and then wash slides in Tris / saline 
for three 2 minutes changes. 
8. Incubate sections in swine anti-rabbit IgG diluted 1:20 for 30 
minutes. 
9. Jet wash off excess antiserum and then wash slides for three 2 
minutes changes. 
10. Incubate sections in PAP complex diluted 1:60 in 1% normal swine 
serum in Tris / saline for 30 minutes. 
11. Jet wash off excess complex and wash in Tris / saline for three 2 
minutes changes. 
12. Incubate sections in DAB medium for 5 minutes. 
13. Wash sections in running water for 10 minutes. 
14. Counterstain in alum hematoxylin, dehydrate, clear and mount. 
Results: 
Reaction product          ……             brown 
Nuclei                           ……             blue 
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S.No OP/IP No HP No Age Sex Liver Spleen
Adeno
pathy
Abdominal 
Mass
Mediasti
nal    
mass
Peripheral 
smear
Histopathology Special stain   IHC Final Diagnosis by 
IHC
1 48596 1956/08 3.5yrs F   ‐‐   ‐‐        ‐‐             +             ‐‐            N Neuroblastoma chr +
2 50632 2161/08 60yrs M   ‐‐   ‐‐        +             ‐‐             ‐‐            N NHL Reticulin
3 51948 2236/08 16 yrs M   ‐‐   ‐‐       ‐‐             ‐‐             ‐‐            N Ewings sarcoma PAS
4 51090 2346/08 12 yrs M   ‐‐   ‐‐        ‐‐             +             ‐‐            N Wilms tumor 
5 5252 2675/08 41yrs M   ‐‐   ‐‐        +             ‐‐             +            N NHL Reticulin
6 68649 3223/08 26 yrs M   ‐‐   ‐‐       ‐‐            +             ‐‐            N
Intra abdominal
desmoplastic tumor
7 67099 3283/08 5 yrs M   ‐‐   ‐‐        +             ‐‐             ‐‐            N NHL Reticulin
8 35280 3434/08  9 yrs  F   ‐‐   ‐‐        +             ‐‐             +            N NHL Reticulin
9 82399 3967/08 48 yrs M   ‐‐   ‐‐        +             ‐‐             +            N NHL Reticulin
10 83704 3973/08 13 yrs M   ‐‐   ‐‐          ‐‐             ‐‐             ‐‐            N Ewings sarcoma PAS
11 85837 3998/08 13 yrs M   ‐‐   ‐‐          ‐‐             ‐‐             ‐‐            N Ewings sarcoma CD 99 +
12 84185 4012/08 11 yrs F    +      +           +             ‐‐               +            N NHL Reticulin
13 86281 4482/08 15 yrs F   ‐‐   ‐‐          ‐‐             ‐‐             ‐‐            N
Malignant round
blue cell tumor
PAS
CD 99+
 vimentin+ 
desmin,chr,
LCA ‐ 
ewings sarcoma
14 96928 4670/08 4 yrs F   ‐‐   ‐‐          ‐‐              +             ‐‐            N Wilms tumor
15 106228 70/09 46 yrs M   ‐‐   ‐‐          +             ‐‐              +
 ? CLL/
? Lmphoma
NHL with luekemic
dissemination
Reticulin
16 101628 117/09 58 yrs M    ‐‐    ‐‐         ‐‐             ‐‐             ‐‐             N
Malignant round
blue cell tumor
CD 99,
 vimentin,
desmin,chr,
LCA ‐ 
Undifferentiated 
malignant round
blue cell tumor
17 36768 1193/09 55yrs  F    ‐‐    ‐‐          +             ‐‐             ‐‐             N NHL Reticulin
18 31090 864/09 21 yrs  M    ‐‐    ‐‐          +             ‐‐              +             N NHL Reticulin
19 22394 865/09 3 yrs  F    ‐‐    ‐‐          ‐‐              +             ‐‐             N Neuroblastoma
20 39777 1267/09 55yrs  M    ‐‐    ‐‐          +              ‐‐                ‐‐             N NHL Reticulin
21 49232 1665/09 23yrs F    ‐‐    ‐‐          +              ‐‐                ‐‐             N NHL Reticulin
22 53438 2092/09 8yrs F    ‐‐    ‐‐          ‐‐              ‐‐                ‐‐             N
Malignant round
blue cell tumor
PAS
CD 99+
 vimentin+ 
desmin,chr,
LCA ‐  ewings sarcoma
23 68330 2774/09 52yrs M    ‐‐    ‐‐          +               +                +             N NHL Reticulin
24 62623 3001/09 8yrs M    ‐‐    ‐‐          ‐‐              ‐‐                ‐‐             N Wilms tumor
25 82535 3169/09 3/12mon M    ‐‐    ‐‐          ‐‐              ‐‐                ‐‐             N
Embryonal
rhabdomyosarcoma
desmin +
MASTER CHART
ANNEXURE‐IV
S.No OP/IP No HP No Age Sex Liver Spleen
Adeno
pathy
Abdominal 
Mass
Mediasti
nal    
mass
Peripheral 
smear
Histopathology Special stain   IHC Final Diagnosis by 
IHC
26 75350 3192/09 38yrs F    ‐‐    ‐‐          ‐‐              ‐‐                +             N
Extra skeletal
mesenchymal
chondrosarcoma
27 81871 3318/09 48yrs M    ‐‐    ‐‐          ‐‐              ‐‐                ‐‐             N Ewings sarcoma/PNET PAS
28 92630 3697/09 6yrs F    ‐‐    ‐‐          ‐‐              ‐‐                ‐‐             N Rhabdomyosarcoma
TdT ,CD3,CD45+
Desmin‐‐
NHL
29 94621 3733/09 6/12mon M    ‐‐    ‐‐          ‐‐               +                ‐‐             N Wilms tumor  vimentin +
30 92905 3743/09 60yrs M    ‐‐    ‐‐          +               ‐‐                +             N NHL Reticulin
31 98298 3920/09 20 yrs F    ‐‐    ‐‐          ‐‐               ‐‐               ‐‐             N Ewings sarcoma
CD 99 +,
vimentin+
32 106526 255/10 56yrs M    ‐‐    ‐‐          ‐‐               ‐‐               ‐‐             N NHL              ‐‐
33 27290 1304/10 2 1/2 yrs  M    ‐‐    ‐‐          ‐‐               ‐‐               ‐‐             N
Malignant round
blue cell tumor           
CD 99,
 vimentin,
desmin,chr,
LCA ‐ 
Undifferentiated 
malignant round
blue cell tumor       
34 22536 1546/10 92 yrs M    ‐‐    ‐‐          ‐‐               ‐‐               ‐‐             N NHL               ‐‐ LCA +
35 5761 439/09 12yrs M     ‐‐    ‐‐          ‐‐          ‐‐            ‐‐            N Small cell osteosarcoma
36 372587 2249/08 6mon F    ‐‐    ‐‐           +              +              ‐‐             N Wilms tumor chr‐‐
37 337846 2824/08 54yrs M    ‐‐    +           +              ‐‐               +             N NHL Reticulin
38 391309 3170/08 23yrs M    ‐‐    ‐‐           +              ‐‐               +             N NHL Reticulin
39 379428 2127/10 15 yrs M    ‐‐    ‐‐    ‐‐          +    ‐‐            N NHL               ‐‐
40 381465 2001/08 15yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N PNET
41 381804 2056/08 52yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N
Olfactory
neuroblastoma
chr,S100+
ck‐‐
42 391882 2130/08 70yrs M    ‐‐    ‐‐           +              +              ‐‐             N NHL              ‐‐
43 138828 2161/08 6yrs F    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N Neuroblastoma ck ‐‐,vimentin +
44 141929 3591/08 25yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N
Malignant round
 blue cell tumor
CD 99,vimentin+
desmin,LCA‐‐ ewings sarcoma
45 458851 238/09 35yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N NHL              ‐‐ LCA+,ck‐‐
46 403046 322/09 45yrs M    ‐‐    ‐‐           +              ‐‐              +             N NHL Reticulin LCA+,ck‐‐
47 387831 327/09 6yrs M    ‐‐    ‐‐           ‐‐              +              ‐‐             N Wilms tumor
48 404170 488/09 60yrs M    ‐‐    ‐‐           +              ‐‐              ‐‐             N NHL Reticulin
49 405561 598/09 5yrs F    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N
Embryonal
rhabdomyosarcoma
50 408239 879/09 46yrs M    ‐‐    ‐‐          +              ‐‐              +             N NHL Reticulin
51 408921 922/09 63yrs M    ‐‐    ‐‐          +              ‐‐              ‐‐             N NHL Reticulin
52 412055 1259/09 54yrs F    ‐‐    ‐‐           ‐‐              +              ‐‐             N NHL              ‐‐ ck‐‐,LCA+
53 412205 1264/09 12yrs F    ‐‐    ‐‐           ‐‐              ‐‐              +             N
Embryonal
rhabdomyosarcoma
54 415344 2442/10 14yrs F    ‐‐    ‐‐           ‐‐              +              ‐‐             N NHL              ‐‐
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mass
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55 405661 1709/09 42yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N
Malignant round blue cell 
tumor
             ‐‐
CD 99,
 vimentin,
desmin,chr‐‐
LCA +            NHL
56 419067 1950/09 4yrs F    ‐‐    ‐‐           ‐‐              +              ‐‐             N NHL              ‐‐
57 419608 1659/09 1yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N
Embryonal
rhabdomyosarcoma
58 420379 2089/09 21yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N
Embryonal
rhabdomyosarcoma
59 420853 2553/09 77yrs M    ‐‐    ‐‐           +              ‐‐              ‐‐             N NHL Reticulin
60 421283 2910/09 70yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N NHL              ‐‐
61 428986 3009/09 1yrs F    ‐‐    ‐‐           ‐‐              +              ‐‐             N Wilms tumor
62 429796 3011/09 69yrs F    ‐‐    ‐‐           +              +              ‐‐             N NHL Reticulin
63 433310 3364/09 21yrs F    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N
Botryoid variant of
embryonal RMS
64 435413 3547/09 60yrs F    ‐‐    ‐‐           +              ‐‐              +             N NHL Reticulin
65 435873 3593/09 20yrs M    ‐‐    ‐‐           ‐‐              ‐‐              ‐‐             N
Alveolar 
Rhabdomyosarcoma
desmin+
vimentin,ck ‐‐
66 437342 3725/09 63yrs M    ‐‐    ‐‐          +             ‐‐             ‐‐            N NHL Reticulin
67 438465 s432/10 40yrs M    ‐‐    ‐‐           +              ‐‐              ‐‐             N
Malignant round blue cell 
tumor
CD99,CD100+
vimentinpatchy +
desmin ‐
ewings sarcoma
/ PNET
68 439872 s638/10 68yrs M    ‐‐    ‐‐           +              ‐‐              +             N NHL Reticulin
69 439965 s646/10 45yrs F    ‐‐    ‐‐           +              ‐‐              ‐‐             N NHL Reticulin ck ‐‐,CD 45+
70 455364 G371/10 5yrs F    ‐‐    ‐‐           ‐‐              +              ‐‐             N Neuroblastoma
ck,desmin,chr‐‐
syn patchy +
CHR LCA  CK cytokeratin SYN Synaptophysin
+ Positive Finding ‐‐ Negative Finding
Chromogranin  Leukocyte common antigen 
  
 
 
 
 
 
 
 
 
 
Fig .1: NHL Lymph node: Cut surface is homogenous gray white (864/09) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig .2: NHL Lymph node: Shows structure of lymph node with  
effacement of architecture H&EX100 (864/09) 
  
 
 
 
 
 
 
 
 
 
Fig 3: NHL Lymph node: Shows monotonous proliferation of lymphocytes  
with scanty cytoplasm and regular round nuclei H&EX 400(864/09) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig .4: NHL Lymph node shows loss of architecture with pericellular fibrils 
Reticulin X 400 (864/09) 
 
  
 
 
 
 
 
 
 
 
Fig 5: NHL Parotid gland: Shows skin with underlying homogenous 
gray white mass (1546/10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 6: NHL Parotid gland: Shows diffuse arrangement of monotonus population 
of lymphoid cells H&E X 100(1546/10) 
  
 
 
 
 
 
 
 
 
Fig 7: NHL Parotid gland: Shows salivary ducts surrounded by monotonous population  
of lymphoid cells H&E X 400(1546/10) 
 
 
 
Fig 8: NHL Parotid gland:   Lymphoid cells showing membranous positivity for  
CD 45 (LCA) IHC X400(1546/10) 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 9 :NHL  Stomach: Cut  surface shows homogenous gray white  tumor 
involving more than 2/3 of stomach (2127/10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10: NHL stomach: Shows mucosal glands surrounded by monotonous 
population of lymphoid cells H&E  X100 (2127/10) 
 
  
 
 
 
 
 
 
 
 
Fig 11:NHL stomach: Shows mucosal glands infiltrated by lymphocytes 
(Lymphoepithelial lesion) H&E X400(2127/10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 12 : NHL stomach: Tumor cells show membranous positivity for 
CD 45(LCA) inset shows negativity for cytokeratin X100 IHC (2127/10) 
  
 
 
 
 
 
 
 
 
Fig 13: NHL small intestine: cut surface shows proliferative growth in 
 distal end of ileum (2442/10) 
 
 
Fig 14: NHL small Intestine : monotonous proliferation of lymphocytes. H&E X 100  
inset‐Tumor cells with scanty cytoplasm and round nuclei H&E X 400 (2442/10) 
 
 
 
 
Fig15: Ewing’s sarcoma/PNET :  Uniform round blue cells arranged in lobules H&E X 100  
Inset : Small round blue cells with rosette pattern H&E X 400 (3591/08) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 16: Ewing’s sarcoma/PNET: Showing abundant cytoplasmic 
 glycogen.PAS X400(3591/08) 
 
  
 
 
 
 
 
 
 
 
 
 
Fig 17: Ewing’s sarcoma/PNET: Shows membrane immunoreactivity for CD 99 
IHC X100(3591/08) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 18: Ewing’s sarcoma/PNET: Shows cytoplasmic positivity for vimentin 
IHCX 400(3591/08) 
 
  
 
 
 
 
 
 
 
 
 
Fig 19: Rhabdomyosarcoma:  Shows structure of skin with underlying    
small  round blue cells arranged in nests and diffuse sheets H&EX100( 3169/09) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 20: Rhabdomyosarcoma:   Shows primitive round to   ovoid cells   with 
scanty cytoplasm and round blue nuclei H&E X400(3169/09) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig 21: Rhabdomyosarcoma: Tumor cells show diffuse cytoplasmic positivity for 
desmin IHC X 100 (3169/09) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 22: Alveolar RMS: Cross section shows grayish white 
to tan in colour (3593/09) 
 
 
Fig 23: Alveolar RMS: Shows aggregates of tumor cells separated by thick fibrous septa  
with alveolar pattern H&E X100 (3593/09) 
 
 
 
Fig 24: Alveolar RMS : shows round blue cells with  
scanty cytoplasm and round nuclei H&E X 400 (3593/09) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 25: Wilm’s tumor: Shows more than 2/3 of kidney replaced by 
gray white tumor tissue with hemorrhagic areas (2346/08) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 26: Wilm’s tumor: shows combination of epithelial, blastemal and 
mesenchymal components H&E X100 (2346/08) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig27: Wilm’s tumor: shows epithelial tubular formation, blastemal and 
mesenchymal components H&E X400 (2346/08) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig28: Wilm’s tumor: shows cytoplasmic immunoreactivity for vimentin 
IHC  X400 (2346/08) 
 
 
Fig 29: Neuroblastoma:  Tumor cells arranged in nests and separated by 
delicate fibrous septa H&E X 100 Inset shows uniform  
round blue cells with rosette formation( 1956/08) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 30: Neuroblastoma:  Shows cytoplasmic granular positivity  
for chromogranin IHC X 100( 1956/08) 
 
  
 
 
 
 
 
 
 
 
 
Fig 31: Extra skeletal Mesenchymal Chondrosarcoma: Shows bimorphic pattern with 
cartilaginous area and small round blue cells H & E X100.  
Inset shows undifferentiated cells (3192/09) 
 
 
 
 
 
 
 
 
 
 
 
Fig 32: Small cell Osteosarcoma: Shows neoplastic osteoid with  
nests of tumor cells H&E X100.Inset shows small round cells (439/09) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig 33: DSRCT: Shows nests small round cells surrounded by desmoplastic stroma 
H&E X100. Inset shows nests of small round blue cells (3223/08) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 34: Undifferentiated Malignant Round Blue Cell Tumor: Shows negativity in all of the 
initial antibody markers IHC X 400 (1304/10) 
 
